DMAC Insider Trading
Insider Ownership Percentage: 7.20%
Insider Buying (Last 12 Months): $3,000,000.00
Insider Selling (Last 12 Months): $0.00
DiaMedica Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at DiaMedica Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
DiaMedica Therapeutics Share Price & Price History
Current Price: $3.47
Price Change: ▼ Price Decrease of -0.04 (-1.14%)
As of 04/16/2025 05:00 PM ET
DiaMedica Therapeutics Insider Trading History
DiaMedica Therapeutics Institutional Trading History
Data available starting January 2016
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More on DiaMedica Therapeutics
Volume
84,332 shs
Average Volume
73,377 shs
Market Capitalization
$148.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.5
Who are the company insiders with the largest holdings of DiaMedica Therapeutics?